

Sara C Meyer

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2542053/publications.pdf>

Version: 2024-02-01

25
papers

1,012
citations

687363

13
h-index

610901

24
g-index

25
all docs

25
docs citations

25
times ranked

1952
citing authors

#	ARTICLE	IF	CITATIONS
1	Molecular Pathways: Molecular Basis for Sensitivity and Resistance to JAK Kinase Inhibitors. <i>Clinical Cancer Research</i> , 2014, 20, 2051-2059.	7.0	140
2	CHZ868, a Type II JAK2 Inhibitor, Reverses Type I JAK Inhibitor Persistence and Demonstrates Efficacy in Myeloproliferative Neoplasms. <i>Cancer Cell</i> , 2015, 28, 15-28.	16.8	124
3	Combined Targeting of JAK2 and Bcl-2/Bcl-xL to Cure Mutant JAK2-Driven Malignancies and Overcome Acquired Resistance to JAK2 Inhibitors. <i>Cell Reports</i> , 2013, 5, 1047-1059.	6.4	116
4	Translational implications of somatic genomics in acute myeloid leukaemia. <i>Lancet Oncology</i> , The, 2014, 15, e382-e394.	10.7	106
5	Loss of <i>Ezh2</i> synergizes with <i>JAK2</i> -V617F in initiating myeloproliferative neoplasms and promoting myelofibrosis. <i>Journal of Experimental Medicine</i> , 2016, 213, 1479-1496.	8.5	101
6	Targeting compensatory MEK/ERK activation increases JAK inhibitor efficacy in myeloproliferative neoplasms. <i>Journal of Clinical Investigation</i> , 2019, 129, 1596-1611.	8.2	84
7	Cooperative Epigenetic Remodeling by TET2 Loss and NRAS Mutation Drives Myeloid Transformation and MEK Inhibitor Sensitivity. <i>Cancer Cell</i> , 2018, 33, 44-59.e8.	16.8	71
8	Amotosalen/ultraviolet A pathogen inactivation technology reduces platelet activatability, induces apoptosis and accelerates clearance. <i>Haematologica</i> , 2017, 102, 1650-1660.	3.5	49
9	JAK2 exon 12 mutant mice display isolated erythrocytosis and changes in iron metabolism favoring increased erythropoiesis. <i>Blood</i> , 2016, 128, 839-851.	1.4	35
10	Mediator Kinase Phosphorylation of STAT1 S727 Promotes Growth of Neoplasms With JAK-STAT Activation. <i>EBioMedicine</i> , 2017, 26, 112-125.	6.1	35
11	Mechanisms of Resistance to JAK2 Inhibitors in Myeloproliferative Neoplasms. <i>Hematology/Oncology Clinics of North America</i> , 2017, 31, 627-642.	2.2	32
12	Challenges and Perspectives for Therapeutic Targeting of Myeloproliferative Neoplasms. <i>HemaSphere</i> , 2021, 5, e516.	2.7	24
13	Dual targeting of JAK2 and ERK interferes with the myeloproliferative neoplasm clone and enhances therapeutic efficacy. <i>Leukemia</i> , 2021, 35, 2875-2884.	7.2	19
14	Severe cutaneous toxicity related to Eltrombopag. <i>British Journal of Haematology</i> , 2013, 160, 412-414.	2.5	13
15	Genetics of Myeloproliferative Neoplasms. <i>Hematology/Oncology Clinics of North America</i> , 2021, 35, 217-236.	2.2	13
16	MPN patients with low mutant <i>JAK2</i> allele burden show late expansion restricted to erythroid and megakaryocytic lineages. <i>Blood</i> , 2020, 136, 2591-2595.	1.4	12
17	JAK2 in Myeloproliferative Neoplasms: Still a Protagonist. <i>Pharmaceuticals</i> , 2022, 15, 160.	3.8	11
18	Renal post-mortem findings in myeloproliferative and myelodysplastic/myeloproliferative neoplasms. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2021, 479, 1013-1020.	2.8	10

#	ARTICLE	IF	CITATIONS
19	Anti-Platelet Factor 4/Heparin Antibody Formation Occurs Endogenously and at Unexpected High Frequency in Polycythemia Vera. <i>BioMed Research International</i> , 2017, 2017, 1-13.	1.9	7
20	Co-Occurring CSF3R W791* Germline and Somatic T618I Driver Mutations Induce Early CNL and Clonal Progression to Mixed Phenotype Acute Leukemia. <i>Current Oncology</i> , 2022, 29, 805-815.	2.2	3
21	In response to the comment by Hechler <i>et al</i> : Amotosalen/UVA pathogen inactivation technology reduces platelet activatability, induces apoptosis and accelerates clearance.. <i>Haematologica</i> , 2017, 102, e504-e505.	3.5	2
22	Current Concepts of Pathogenesis and Treatment of Philadelphia Chromosome-Negative Myeloproliferative Neoplasms. <i>Hamostaseologie</i> , 2021, 41, 197-205.	1.9	2
23	Addition of Omega-3 ω -Linolenic Acid to Platelet Apheresis Units Preserves Platelet Activatability Over Time and Reduces Baseline Activation Under Routine Storage Conditions: A Pilot Study. <i>Blood</i> , 2012, 120, 3433-3433.	1.4	2
24	Recent Advances in Molecular Diagnostics and Targeted Therapy of Myeloproliferative Neoplasms. <i>Cancers</i> , 2021, 13, 5035.	3.7	1
25	Prognostic Impact of Iron Overload During Follow-up After Allogeneic Stem Cell Transplantation. <i>Blood</i> , 2011, 118, 347-347.	1.4	0